Limited data are available on the safety and efficacy of immune checkpoint inhibitors (ICI) in patients with preexisting autoimmune diseases (PAD).
Retrospective study of patients with PAD referred for rheumatologic evaluation prior to starting or during immunotherapy between January 2013 and July 2019 from 10 academic sites across Canada. Data were extracted by chart review using a standardized form.
Twenty-seven patients with PAD on ICI therapy were identified. The most common PADs were rheumatoid arthritis (30%), psoriasis/psoriatic arthritis (30%), inflammatory bowel disease (IBD, 15%) and axial spondyloarthritis (11%), and the most frequently observed cancers were lung cancer and melanoma. All patients received anti-PD-1 therapies, and 2 received additional sequential anti-CTLA-4 therapy. PAD exacerbations occurred in 52% over a median (IQR) follow-up of 11.0 (6.0–17.5) months, with 14% being severe, 57% requiring corticosteroids, 50% requiring immunosuppression and 14% requiring ICI discontinuation. Flares were generally more frequent and severe in patients who previously required more intensive immunosuppression (i.e., biologics). Flares occurred despite background immunosuppression at the time of ICI initiation. In patients with preexisting psoriasis, IBD and axial spondyloarthritis, rheumatic immune-related adverse events (irAEs), mostly polyarthritis and tenosynovitis, were frequently observed. Tumor progression was not associated with exposure to immunosuppressive drugs before or after ICI initiation and was numerically less frequent in patients with irAEs.
PAD exacerbations in the context of ICI treatment are common, although generally mild, and occur despite background immunosuppression. Exacerbations are more frequent and severe in patients on more intensive immunosuppressive therapies pre-immunotherapy.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
The data underlying this article will be shared on reasonable request to the corresponding author.
Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S et al (2016) Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54:139–148
Kennedy LC, Bhatia S, Thompson JA, Grivas P (2019) Preexisting autoimmune disease: implications for immune checkpoint inhibitor therapy in solid tumors. J Natl Compr Canc Netw 17:750–757
Tison A, Quéré G, Misery L, Funck-Brentano E, Danlos FX, Routier E et al (2019) Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: a nationwide, multicenter cohort study. Arthritis Rheumatol 71:2100–2111
Cortellini A, Buti S, Santini D, Perrone F, Giusti R, Tiseo M et al (2019) Clinical outcomes of patients with advanced cancer and pre-existing autoimmune diseases treated with anti-programmed death-1 immunotherapy: a real-world transverse study. Oncologist 24:e327–e337
Leonardi GC, Gainor JF, Altan M, Kravets S, Dahlberg SE, Gedmintas L et al (2018) Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders. J Clin Oncol 36:1905–1912
Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ et al (2017) Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol 28:368–376
Martinez Chanza N, Xie W, Issa M, Dzimitrowicz H, Tripathi A, Beuselinck B et al (2020) Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study. J Immunother Cancer 8(1):e000538
Danlos FX, Voisin AL, Dyevre V, Michot JM, Routier E, Taillade L et al (2018) Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. Eur J Cancer 91:21–29
U.S. Department of Health and Human Sciences NIoH, (2020) National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 Published: November 27, 2017 [October 12, 2020]. Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf.
Roberts J, Ennis D, Hudson M, Ye C, Saltman A, Himmel M et al (2020) Rheumatic immune-related adverse events associated with cancer immunotherapy: a nationwide multi-center cohort. Autoimmun Rev 19:102595
Esfahani K, Miller WH Jr (2017) Reversal of autoimmune toxicity and loss of tumor response by interleukin-17 blockade. N Engl J Med 376:1989–1991
Barbacki A, Maliha PG, Hudson M, Small D (2018) A case of severe Pembrolizumab-induced neutropenia. Anticancer Drugs 29:817–819
Zamani MR, Aslani S, Salmaninejad A, Javan MR, Rezaei N (2016) PD-1/PD-L and autoimmunity: a growing relationship. Cell Immunol 310:27–41
Chen H, Peng Q, Yang H, Yin L, Shi J, Zhang Y et al (2018) Increased levels of soluble programmed death ligand 1 associate with malignancy in patients with dermatomyositis. J Rheumatol 45:835–840
Guo Y, Walsh AM, Canavan M, Wechalekar MD, Cole S, Yin X et al (2018) Immune checkpoint inhibitor PD-1 pathway is down-regulated in synovium at various stages of rheumatoid arthritis disease progression. PLoS ONE 13:e0192704
Kobayashi M, Kawano S, Hatachi S, Kurimoto C, Okazaki T, Iwai Y et al (2005) Enhanced expression of programmed death-1 (PD-1)/PD-L1 in salivary glands of patients with Sjögren’s syndrome. J Rheumatol 32:2156–2163
Arbour KC, Mezquita L, Long N, Rizvi H, Auclin E, Ni A et al (2018) Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol 36:2872–2878
Fucà G, Galli G, Poggi M, Lo Russo G, Proto C, Imbimbo M et al (2019) Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. ESMO Open 4:e000457
Warner BM, Baer AN, Lipson EJ, Allen C, Hinrichs C, Rajan A et al (2019) Sicca syndrome associated with immune checkpoint inhibitor therapy. Oncologist 24:1259–1269
Abu-Sbeih H, Faleck DM, Ricciuti B, Mendelsohn RB, Naqash AR, Cohen JV et al (2020) Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease. J Clin Oncol 38:576–583
Nakanishi Y, Masuda T, Yamaguchi K, Sakamoto S, Horimasu Y, Nakashima T et al (2019) Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer. Respir Investig 57:451–459
Kanai O, Kim YH, Demura Y, Kanai M, Ito T, Fujita K et al (2018) Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease. Thorac Cancer 9:847–855
Shibaki R, Murakami S, Matsumoto Y, Yoshida T, Goto Y, Kanda S et al (2020) Association of immune-related pneumonitis with the presence of preexisting interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody. Cancer Immunol Immunother 69:15–22
Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S et al (2019) Management of immunotherapy-related toxicities, version 1.2019. J Natl Compr Canc Netw 17:255–89
No specific funding was received from any bodies in the public, commercial or not-for-profit sectors to carry out the work described in this article.
Conflict of interest
The authors have no conflicts of interest to declare that are relevant to the content of this article.
This submission represents original work that is not under consideration elsewhere and that has not been previously published. All authors participated in the preparation of the manuscript. All authors meet criteria for authorship and will sign a statement attesting authorship, disclosing all potential conflicts of interest and releasing the copyright should the manuscript be acceptable for publication.
Consent to participate
Patient consent was waived due to the retrospective nature of the study.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Hoa, S., Laaouad, L., Roberts, J. et al. Preexisting autoimmune disease and immune-related adverse events associated with anti-PD-1 cancer immunotherapy: a national case series from the Canadian Research Group of Rheumatology in Immuno-Oncology. Cancer Immunol Immunother (2021). https://doi.org/10.1007/s00262-021-02851-5
- Adverse events
- Checkpoint inhibitor